An intranasal ASO therapeutic targeting SARS-CoV-2

The COVID-19 pandemic is exacting an increasing toll worldwide, with new SARS-CoV-2 variants emerging that exhibit higher infectivity rates and that may partially evade vaccine and antibody immunity. Rapid deployment of non-invasive therapeutic avenues capable of preventing infection by all SARS-CoV...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Chi, Lee, Justin Y., Woo, Jia Z., Xu, Lei, Nguyenla, Xammy, Yamashiro, Livia H., Ji, Fei, Biering, Scott B., Van Dis, Erik, Gonzalez, Federico, Fox, Douglas, Wehri, Eddie, Rustagi, Arjun, Pinsky, Benjamin A., Schaletzky, Julia, Blish, Catherine A., Chiu, Charles, Harris, Eva, Sadreyev, Ruslan I., Stanley, Sarah, Kauppinen, Sakari, Rouskin, Silvi, Näär, Anders M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9349213/
https://www.ncbi.nlm.nih.gov/pubmed/35922434
http://dx.doi.org/10.1038/s41467-022-32216-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9349213/
https://www.ncbi.nlm.nih.gov/pubmed/35922434
http://dx.doi.org/10.1038/s41467-022-32216-0

Ejemplares similares